Integrating homologous recombination deficiency subtyping with TCGA molecular classification for enhanced prognostic stratification and personalised therapy in endometrial cancer
HRD subtyping refines risk stratification beyond traditional TCGA classification and identifies patients potentially responsive to immune checkpoint or DNA damage-targeted therapies. Integrating HRD-based genomic instability metrics with molecular and immune profiling supports precision oncology in endometrial cancer.
Authors
- Hong Zheng (ORCID: https://orcid.org/0000-0002-2453-0992)
- Naiyi Zhang
- Hongguo Wang
- Yunong Gao
- Nan Zhang (ORCID: https://orcid.org/0000-0001-6518-2501)
- Wei Wang (ORCID: https://orcid.org/0000-0001-5896-8821)
- Weijiao Gao (ORCID: https://orcid.org/0009-0007-1276-4752)
- Min Gao (ORCID: https://orcid.org/0000-0002-2225-8243)
- Tong Shu (ORCID: https://orcid.org/0000-0002-6923-4708)
- Nan Song (ORCID: https://orcid.org/0000-0002-9176-0886)
Institutions
- Ministry of Education (ET)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1038/s41416-025-03179-y
- Citations
- 1
- Primary Topic
- RNA Research and Splicing
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- National Natural Science Foundation of China